A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-part Study of Orally Administered JNJ-54257099 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1) and Food-effect (Part 2) in Healthy Subjects, and Multiple Doses in Subjects With Chronic Hepatitis C Infection (Part 3)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-part Study of Orally Administered JNJ-54257099 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1) and Food-effect (Part 2) in Healthy Subjects, and Multiple Doses in Subjects With Chronic Hepatitis C Infection (Part 3)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs AL 704 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Alios BioPharma
  • Most Recent Events

    • 28 Jan 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 21 Dec 2015 According to Medivir media release, company has terminated the development of this drug based upon the acceptable safety and pharmacokinetics results of this trial.
    • 03 Aug 2015 Status changed from planning to recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top